{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:13:04Z","timestamp":1785600784818,"version":"3.56.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Immunotherapy with T cells engineered to express a chimeric antigen receptor (CAR T cells) is reshaping the management of patients with relapsed or refractory B-cell malignancies. High efficacy of CD19-targeted CAR T cells has been reported in children and adults with B-cell acute lymphoblastic leukemia (B-ALL), with complete responses without detectable minimal residual disease occurring in approximately 80% to 90% of patients. This led to the approval of tisagenlecleucel (Kymriah) by the Food and Drug Administration based on the results of the ELIANA trial. Although CD19 CAR T-cell therapy may be curative in children, responses are short-lived in most adult B-ALL patients. In addition, CAR T-cell therapy can be associated with severe, potentially life-threatening, toxicities, such as cytokine release syndrome and immune effector cell\u2013associated neurotoxicity syndrome. Here, we review the recent advances in CAR T-cell therapy for R\/R B-ALL and discuss strategies to improve its efficacy while minimizing toxicities.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000508","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T07:13:37Z","timestamp":1616224417000},"page":"98-106","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1097","volume":"27","author":[{"given":"Jordan","family":"Gauthier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","year":"2012","journal-title":"Blood"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","year":"2016","journal-title":"Haematologica"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3324\/haematol.2015.131680","article-title":"Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome","volume":"101","year":"2016","journal-title":"Haematologica"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bbmt.2013.04.014","article-title":"Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"19","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/bmt.2016.224","article-title":"Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience","volume":"52","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","year":"2019","journal-title":"Blood"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","year":"2016","journal-title":"J Clin Investig"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","year":"2020","journal-title":"Blood Adv"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib12-20250621","first-page":"7006","article-title":"End of phase I results of ZUMA-3, a phase 1\/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed\/refractory (R\/R) acute lymphoblastic leukemia (ALL)","volume":"37","year":"2019","journal-title":"ASCO Abstract"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","year":"2015","journal-title":"Lancet (London, England)"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","year":"2017","journal-title":"Leukemia"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ajh.25274","article-title":"Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia","volume":"93","year":"2018","journal-title":"Am J Hematol"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","article-title":"Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a Pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood-2019-131086","article-title":"AUTO1, a novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","year":"2014","journal-title":"Blood"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"bib25-20250621","first-page":"50","article-title":"Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy","volume":"66","year":"2018","journal-title":"Curr Res Transl Med"},{"key":"bib26-20250621","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.bbmt.2018.12.410","article-title":"Tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia: updated analysis of the ELIANA clinical trial","volume":"25","year":"2019","journal-title":"Biol Blood Marrow Tr"},{"key":"bib29-20250621","first-page":"1","article-title":"Factors predicting long-term survival following CD19 CAR T-cell therapy in relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib30-20250621","first-page":"14","article-title":"Disease burden impacts outcomes in pediatric and young adult B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel: results from the Pediatric Real World CAR Consortium (PRWCC)","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","year":"2019","journal-title":"Blood"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","year":"2019","journal-title":"Blood Adv"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","year":"2016","journal-title":"Nat Commun"},{"key":"bib35-20250621","first-page":"13","article-title":"Pre-CAR blinatumomab is associated with increased post-CD19 CAR relapse and decreased event free survival","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1038\/s41375-020-0831-z","article-title":"Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r\/r B-ALL children","volume":"34","year":"2020","journal-title":"Leukemia"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1357","article-title":"Immortal time bias in observational studies of drug effects","volume":"16","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","year":"2010","journal-title":"BMJ"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"1073274818789355","DOI":"10.1177\/1073274818789355","article-title":"Immortal time bias in observational studies of time-to-event outcomes","volume":"25","year":"2018","journal-title":"Cancer Control"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","article-title":"Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood-2018-99-115599","article-title":"Long term follow-up after SCRI-CAR19v1 reveals late recurrences as well as a survival advantage to consolidation with HCT after CAR T cell induced remission","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib42-20250621","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2018-99-111528","article-title":"Immunotherapy with T-cells engineered with a chimeric antigen receptor bearing a human CD19-binding single chain variable fragment for relapsed or refractory acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib44-20250621","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2019-128286","article-title":"Humanized CD19-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib45-20250621","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"bib46-20250621","first-page":"20","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","year":"2017","journal-title":"Nat Med"},{"key":"bib47-20250621","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","year":"2019","journal-title":"Leukemia"},{"key":"bib48-20250621","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","year":"2020","journal-title":"Blood"},{"key":"bib49-20250621","first-page":"44","article-title":"Tandem CD19\/CD22 dual targets CAR-T cells therapy acquires superior CR rate than CD19 CAR-T cells: a case controlled study","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib50-20250621","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","year":"2018","journal-title":"J Hematol Oncol"},{"key":"bib51-20250621","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"bib52-20250621","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib53-20250621","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.jcyt.2019.04.009","article-title":"Early administration of tocilizumab (Toci) for the prevention of grade 4 cytokine release syndrome (CRS) after CD19-directed CAR T-cell therapy (CTL019)","volume":"21","year":"2019","journal-title":"Cytotherapy"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:03:22Z","timestamp":1750525402000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000508"}},"subtitle":["Current Landscape in 2021"],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000508","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}